suPARnostic® Measures suPAR
Thus, by measuring an individual’s suPARnostic® level, the prognosis can be supported, the need for therapy is indicated and the effect of treatment can be monitored.
We have worked for several years on the measurement of patient samples with suPARnostic® in a number of disease indications. In several studies, some funded and conducted independent of ViroGates, results have led to the conclusion that an elevated suPARnostic® level carries negative prognostic value of patient survival amongst those suffering from some type of infection and/or inflammatory condition - and information that might be crucial in clinical decision-making.
For the moment, these findings extend to HIV, TB, Malaria, Sepsis, bacterial and viral CNS infections, Rheumatoid Arthritis, Multiple Sclerosis, and certain cancers.
For more information about what suPAR is, please read here:
What is suPAR.pdf (119.16 KB)
